Moderna Inc. announced Wednesday a new agreement to supply 25 million doses of its COVID-19 vaccine to Australia. The agreement includes 10 million doses of the biotechnology company’s mRNA-1273 vaccine to be delivered this year and 15 million doses of its variant booster vaccine candidate to be delivered in 2022. The agreement is subject to approval of mRNA-1273 and the booster vaccine candidate by Australia’s Therapeutic Goods Administration. Moderna’s stock, which fell 0.2% in premarket trading, has run up 52.2% year to date through Tuesday, while the S&P 500 has gained 10.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.